TGF␤1 regulates early cortical development by moving young neurons from the proliferative population and promoting their migration. Altered TGF␤1-regulated signaling can lead to abnormal development underlying microencephaly and migratory defects as in attention deficit hyperactivity disorder, dyslexia, and fetal alcohol spectrum disorder. The present study tested the hypotheses that TGF␤1 signals through cross-talking Smad2/3 and extracellular signal-regulated kinase 1/2 (ERK1/2) pathways and that ethanol simulates these TGF␤1-initiated signals. Slices generated from the telencephalons of 17-d-old rat fetuses were treated with TGF␤1 (0 or 10 ng/ml), ethanol (0, 200, 400, or 800 mg/dl), and/or a pharmacological agent [to block phosphorylation of Smad2/3 (SB431542 or LY364947) or ERK1/2 (PD98059 or U0126)]. In some experiments, the proliferative compartment (the ventricular and subventricular zones; S/VZ) and the postproliferative compartment (intermediate zone/cortical plate/marginal zone) were examined separately. Smad2/3 phosphorylation increased following treatment with TGF␤1, ethanol, and PD98059 (or U0126) plus ethanol. In contrast, SB431542 (and LY364947) blocked Smad2/3 activation and led to the phosphorylation of ERK1/2. These changes revealed cross talk between the two TGF␤1-responsive pathways. TGF␤1-induced effects were primarily in the S/VZ, whereas ethanol induced activation in both compartments. In summary, TGF␤1 activates two separate pathways (Smad2/3 and ERK1/2) that actively interact. Ethanol simulates TGF␤1-induced changes in these signaling systems. Each pathway is preferentially activated during specific developmental events: the Smad2/3 pathway is key for cells exiting from the cycling population and the ERK1/2 pathway is particularly inducible during neuronal migration.
Introduction
Defects underlying neurodevelopmental disorders commonly arise from abnormal production and migration of cortical neurons. These disorders include attention deficit hyperactivity disorder, autism, dyslexia, epilepsy, fetal alcohol spectrum disorder (FASD), and schizophrenia (Allen and Walsh, 1999; Galaburda, 2005; Levitt, 2005; Miller, 2006) . The etiology of such disorders is characterized by reduced neuronal numbers and ectopically distributed neurons.
A key player in the early development of cortical neurons is transforming growth factor ␤ (TGF␤). TGF␤ moves proliferating cells out of the cycling population Miller, 2005a,b, 2006) and regulates their migration . TGF␤ ligands and receptors are strategically and spatiotemporally expressed in sites (1) where neurons are generated [the ventricular zone (VZ), subventricular zone (SZ), and ganglionic eminence] and (2) through which neurons migrate [e.g., the intermediate zone (IZ) (Flanders et al., 1991; Pelton et al., 1991; Unsicker et al., 1996; Vivien et al., 1998; Miller, 2003; Siegenthaler and Miller, 2008) ].
TGF␤ signaling has been explored in non-neural cells. Upon ligand binding, the serine/threonine kinase of the receptor is activated which causes the phosphorylation of Smad2/3 (Shi and Massagué, 2003; Gomes et al., 2005) . Activated Smad2/3 associates with Smad4 and the complex translocates to the nucleus where it modulates the transcription of TGF␤-responsive genes (ten Dijke and Hill, 2004) . TGF␤ also may signal via extracellular signal-regulated kinase (ERK) (Brown et al., 1999; Blanchette et al., 2001 ). There may be interplay between the Smad and ERK pathways (Brown et al., 1999; Blanchette et al., 2001; Watanabe et al., 2001; Hayashida et al., 2003) . Whether the interaction is facilitatory or inhibitory depends on the cell type and the extent of ERK activation.
Exposures to neurotoxic substances such as ethanol cause changes that mirror those induced by TGF␤. That is, ethanol can inhibit cell proliferation, cause migration defects, and retard the rate of migration (Miller, 1986 (Miller, , 1988 (Miller, , 1997 Luo and Miller, 1996; Mooney et al., 2004; Miller, 2004, 2005b; Kumada et al., 2006) . Ethanol affects the activation of receptor kinases and ERK (Resnicoff et al., 1993; Luo and Miller, 1999a,b; Kalluri and Ticku, 2003; Chaturvedi and Sarkar, 2005) and alters the expression of cell adhesion molecules critical for neuronal migration Miller et al., 2006) .
Not only do ethanol and TGF␤1 have parallel effects on early developmental processes, TGF␤-mediated growth inhibition can be modified by ethanol. For example, ethanol can antagonize the anti-proliferative action of TGF␤1 by blocking TGF␤1-dependent increases in the cyclin-dependent kinase inhibitor p21 (Siegenthaler and Miller, 2005b) . Ethanol can alter TGF␤1-induced increases in cell adhesion molecules Miller et al., 2006) . In folliculostellate cells, ethanol apparently can activate Smad or alter TGF␤3 activation of Smad2 (Chaturvedi and Sarkar, 2005) . The present study tests two hypotheses. (1) TGF␤1-mediated activities are transduced via bidirectional cross talk between the Smad2/3 and ERK signal transduction pathways. (2) Ethanol interferes with cortical development by interfering with these TGF␤1-mediated signals. These hypotheses were tested in ex vivo preparations of the cerebral walls of fetal rats.
Materials and Methods

Subjects
Timed pregnant Sprague Dawley rats were obtained from Taconic Farms. The animals were housed in a vivarium at the Veterans Affairs Medical Center (VAMC) that was approved by the Association for Assessment and Accreditation of Laboratory Animal Care. Animals were maintained according to protocols approved by the Committee on the Humane Animal Use at Upstate Medical University and the Institutional Animal Care and Use Committee of the Syracuse VAMC. The environment for the rats was tightly maintained. The 12 h light cycle was from 7:00 A.M. to 7:00 P.M. The temperature and humidity were kept between 20 and 21°C and 40 and 70%.
Pregnant dams were killed on gestational day 17 (G17) during the middle of the light cycle, when cell proliferation was at its peak (Miller, 1992) . The dams were anesthetized with 1.0 ml/kg of a mixture of ketamine (100 mg/ml) and xylazine (10.0 mg/ml). Fetuses were removed by Caesarian section, and their brains were collected. The meninges were carefully removed, and the fresh brains were cut into 300 m coronal slices using a McIlwain Tissue Chopper (Mickle Lab Engineering).
Slices were placed into artificial CSF (124 mM NaCl, 5.0 mM KCl, 3.91 mM CaCl 2 , 1.23 mM NaH 2 PO 4 , 26.0 mM NaHCO 2 , 2.0 mM MgSO 4 , and 10.0 mM dextrose). Slices from the fetuses within a particular litter were pooled. Six to eight slices were carefully arranged on a Millicell filter with 0.40-m-wide pores (Millipore). The slices were placed into 35 mm Petri dishes and cultured.
Treatment of the slices
Short-term studies. For the short-term (0 -90 min) treatment studies, a serum-free medium (96% Neurobasal medium, 17.0 mM L-glutamine, 2.0% B-27 and 1.0% N2 supplements, and 1.0% penicillin/streptomycin; all ingredients from Invitrogen) was used. The serum-free conditions were important for being able to ascribe changes to TGF␤1. Previous work in this laboratory (Mooney et al., 2004; Miller, 2004, 2005a,b) and preliminary investigations into the current experiments first used a serum-supplemented medium for 2 h before switching to a serum-free medium. Using these conditions, changes in Smad2/3 phosphorylation were not detectable. Evidently, this was due to a high amount of Smad2/3 phosphorylation that occurred immediately following the switch from a serum-laced to a serum-free medium. Thus, for the short-term studies, freshly prepared slices were immediately placed into a serum-free medium.
Slices were incubated at 37°C with 95% O 2 /5.0% CO 2 for 2 h before treatment. The effects of various substances on the slices were examined. These included TGF␤1 (0 or 10 ng/ml; T7039, Sigma) and ethanol (0, 200, 400, or 800 mg/dl; equivalent to 0, 43.4, 86.8, or 174 mM, respectively). In addition, four pharmacological agents were used. One was SB431542 (0 or 20.0 M; Tocris Cookson), a competitive inhibitor of the ATP binding site kinase that restricted the phosphorylation of immobilized Smads (Inman et al., 2002) without affecting components of the ERK, Jun N-terminal kinase (JNK), or p38 mitogen-activated protein kinase (MAPK) pathways. SB431542 inhibited TGF␤1 and activininduced phosphorylation of Smad, but it did not affect bone morphogenic protein-induced phosphorylation of Smad1 . A second Smad inhibitor, LY364947 (0.0 or 10 M; Tocris Cookson), which inhibits the receptor kinase domain of TGF␤rI, was used to validate findings with SB431542. The ERK1/2 pathway blocker, PD98059 (0 or 100 M; Alexis Biochemicals), inhibited the dephosphorylated form of MAPK kinase (a.k.a. MEK) 1 on S217 and S221 (Alessi et al., 1995) . The specificity of the PD compound was validated with U0126 (0.0 or 10 M), a potent and selective noncompetitive inhibitor of MAP kinase kinase, MEK1 and MEK2. Multiple slices were obtained from each litter. A single litter of fetuses generally produced enough slices to have at least one sample per treatment group at two of the following time points: 0, 5, 10, 15, 30, 60, or 90 min. The data for a single time point represented the mean from samples taken from six to eight litters (n ϭ 6 to 8).
Long-term studies. Long-term effects were examined in slices treated with an exogenous agent for 24 h. To maximize the viability of these slices, they were initially incubated in a medium composed of 20% fetal bovine serum (Invitrogen). After 2 h, the serum-containing medium was replaced with the serum-free medium supplemented with combinations of TGF␤1, ethanol, SB431542, and PD98059 for 24 h. To have enough protein for immunoblotting, seven slices per treatment per litter were pooled. The data for each litter were considered to be a single sample. The data for eight independent litters were run for each treatment (n ϭ 8).
Ethanol stabilization
All cultures were maintained in sealed containers to stabilize the ethanol concentration in the medium (Adickes et al., 1988) . Culture dishes were suspended over a bath containing ethanol in the same concentrations as in the medium, i.e., 0, 200, 400, or 800 mg/dl. Carbon dioxide (5.0%) was added to the chambers immediately before they were sealed. Determination of ethanol concentration was performed in previous studies (Luo and Miller, 1997) . These showed that the ethanol concentration was stable for at least 48 h.
Isolation of tissue samples
Following a treatment, a segment of the cerebral wall was dissected. This segment extended laterally to the lateral extent of the ventricle and medially to the midpoint of the ventricle. Thus, it included the presumptive somatosensory cortex.
Some samples of the cerebral wall were dissected to separate the proliferative and postproliferative zones. This dissection was performed by transilluminating the slices with an external fiber optic light source (Fiberlite MI-150 High Intensity IIluminator, Dolan-Jenner Industries) and viewed through an Olympus dissecting microscope. This enabled discrimination of the interface between the cell body-poor IZ and the relatively cell-rich proliferative zones (the VZ and SZ; collectively described as the S/VZ). Cleavage along this interface was accomplished using two small beaver eye blades (Becton-Dickinson). Thus, the S/VZ and the postproliferative zone [IZ/cortical plate (CP)/marginal zone (MZ)] were isolated. One litter provided enough slices for each treatment group to be tested. A total of six litters were used for this set of experiments (n ϭ 6).
Immunoblotting
Immunoblots were run to examine dynamic changes in Smad2/3 and ERK1/2 regulation and possible interplay between the pathways. Accordingly, tissue was placed in cold RIPA lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1.0% Nonidet P-40, 0.50% sodium deoxycholate, 1.0 mM EDTA, and 0.10% SDS supplemented with a protease inhibitor cocktail (Sigma P-8340), 1.0 mM sodium orthovanadate, and 20 mM sodium fluoride. Samples were homogenized and centrifuged for 10 min at 10,000 rpm. The supernatant was removed and stored at Ϫ20°C before immunoblotting.
The samples were thawed and the protein concentration of the supernatant was determined (Bradford, 1976 ) using the Bio-Rad Protein Assay Kit II (Bio-Rad). Protein samples (30 g) were combined with sample buffer (300 mM Tris-HCl, 50% glycerol, 5.0% SDS, 0.025% bromophe-
nol blue, and 250 mM ␤-mercaptoethanol). The samples and a set of rainbow molecular weight standards (GE Healthcare) were loaded on each 10% SDS-polyacrylamide gel. The proteins were separated electrophoretically by applying a charge of 25-35 mA across the gel for ϳ3 h. Separated proteins were transferred to nitrocellulose membranes. The transfer from the gel to the nitrocellulose membrane was verified by staining the posttransfer gel with a Ponceau reagent (0.10% w/v in 5.0% acetic acid). The immunolabeling followed a three-step procedure.
(1) After blocking nonspecific immunoreactivity with a wash in 5.0% nonfat dehydrated milk (NFDM) for 1 h at room temperature, the membranes were incubated with a primary antibody (supplemental Table 1 , available at www.jneurosci.org as supplemental material). The working dilutions of the antibodies were prepared in 2.5% NFDM. Membranes were incubated overnight with the primary antibody at 4°C. (2) Membranes were rinsed and incubated with either a horseradish peroxidase (HRP)-linked anti-mouse or anti-rabbit secondary antibody. (3) Proteins that were tagged were visualized using a chemiluminescent detection reagent (GE Healthcare) exposed to Kodak Biomax XAR film and developed. All interincubation rinses used 100 mM PBS and 1.0% Tween 20.
␤-Actin expression is unaffected by ethanol treatment. Therefore, ␤-actin was used as a control to ensure that equivalent amounts of protein were loaded onto the lanes. Membranes were stripped in a buffer containing 62.5 mM Tris-HCl, 2.0% SDS, and 10 M ␤-mercaptoethanol at 50°C for 30 min. Nonspecific staining in the membranes was blocked as described above and membranes were reprobed with an anti-mouse ␤-actin antibody (1:2000; Sigma).
The densitometric data from the immunoblots were normalized using a two-step process. The data were first normalized to the ␤-actin to control for any variability in protein concentration due to unequal loading of the lanes. Second, the data were normalized to control samples obtained from the same litter. These steps controlled for interlitter differences attributable to degradation of antibodies and the detection system (ECL) with time and potential differences in separation and transfer efficacy. The values determined after these two normalization steps were taken as relative measures.
Immunohistochemistry
Following either 15 min or 24 h of exposure to a treatment, some slices were fixed in 4.0% paraformaldehyde in 100 mM phosphate buffer (PB) for 30 min at room temperature. Fixed slices were cryoprotected by a wash with a solution of 10% sucrose in PB followed by immersion in a solution of 15% sucrose in PB. Slices were frozen and then cut into 12.5 m sections. Sections were thawed in PBS at room temperature, steamed for 20 min in 10 mM citric acid buffer, pH 6.0, and rinsed in fresh PBS.
The immunolabeling involved a protocol that paralleled the immunoblotting procedure. Sections were steamed for 20 min in 0.010 M citric acid buffer, pH 6.0, and then incubated with the solutions in the Tyramide Signal Amplification Kit (Invitrogen) including a blocking reagent. Three antibodies were used: mouse monoclonal anti-Smad2/3 (1:500 in NFDM; Cell Signaling), rabbit polyclonal anti-phosphorylated Smad2/3 (1:250 in NFDM; Cell Signaling), mouse monoclonal antiphosphorylated p44 (ERK1)/p42 (ERK2) (1:50 in NFDM; Cell Signaling). Sections were incubated with the primary antibody for 2 h.
After the binding the primary antibody, sections were rinsed and incubated with the appropriate secondary antibody-HRP conjugate (1:100 in NFDM) for one hr, rinsed again, and incubated with a tyramide Alexa Fluor 488 dye-labeled streptavidin. All sections were double-labeled with an anti-Ki-67 antibody (1:150 in NFDM; generated in rabbits by NeoMarkers) tagged to a goat anti-rabbit rhodamine-conjugated secondary antibody (Jackson ImmunoResearch Laboratories). The Ki-67 immunostaining allowed for the differentiation of proliferating (Ki-67ϩ) and nonproliferating (Ki-67Ϫ) cells.
Statistical analysis
Differences among the treatment groups in the acute studies were analyzed using a two-way (treatment ϫ time) ANOVA. The chronic studies were analyzed using a one-way ANOVA across treatments. Finally, experiments comparing the regional differences between the proliferative and postproliferative compartments of the developing cerebral wall, a two-way (treatment ϫ zone) ANOVA was run. In the cases where statistically significant ( p Ͻ 0.05) differences were detected, a Student-Newman-Keuls test was performed for pairwise comparisons. There were a few cases an ANOVA across all eight treatment groups revealed no significant differences, yet there was a more than threefold difference between some pairs of means. In these cases, a one-way ANOVA was performed to compare those treatment groups versus controls.
Results
Smad2/3
Short-term effects The effects of various treatments (TGF␤1, ethanol, and TGF␤1 plus ethanol) on total Smad2/3 content and on the amount of activated Smad2/3 were examined in slice cultures of the developing rat cerebral wall. There was a significant main effect of both treatment (F (7,264) ϭ 3.50 p Ͻ 0.001) and time (F (7,264) ϭ 3.03, p Ͻ 0.01) as well as a treatment ϫ time interaction (F (35,264) ϭ 2.31, p Ͻ 0.001) on total Smad2/3 content. Further, there was a significant main effect of treatment (F (7,264) ϭ 6.81, p Ͻ 0.001) and time (F (7,264) ϭ 4.41, p Ͻ 0.001) as well as a treatment ϫ time interaction (F (7,264) ϭ 3.33, p Ͻ 0.001) on the expression of phosphorylated Smad2/3. TGF␤1 did not affect the amount of total Smad2/3 protein; however, it induced significant ( p Ͻ 0.01) increases in the amount of Smad2/3 phosphorylation following treatment for 15 min ( Fig. 1; supplemental Fig. 1 A, Table 2 A, available at www.jneurosci.org as supplemental material).
Specificity of the effects of TGF␤1 was assessed in experiments using the TGF␤1 inhibitors, SB431542 and LY364947, alone and with TGF␤1 ( Fig. 1; supplemental Figs. 1 A, 2A , B, available at www.jneurosci.org as supplemental material). Both compounds significantly ( p Ͻ 0.01) blocked phosphorylation of endogenous Smad2/3 (i.e., in the condition where only the SB431542 was added) and Smad2/3 phosphorylation induced by exogenous TGF␤1 (i.e., when slices were treated with TGF␤1 and SB431542 or LY364947 simultaneously) [data not shown and supplemental Fig. 2 A, B (available at www.jneurosci.org as supplemental material), respectively].
Like TGF␤1, ethanol treatment did not affect the amount of total Smad2/3 protein. On the other hand, ethanol treatment led to a twofold increase in Smad2/3 phosphorylation within 15 min ( p Ͻ 0.05) ( Fig. 1; supplemental Figs. 1 A, 2A , B, available at www.jneurosci.org as supplemental material). Ethanol-induced phosphorylation was also blocked by SB431542 and LY364947.
The combination of TGF␤1 and ethanol did not affect total Smad2/3 protein content. This treatment did produce a significant ( p Ͻ 0.05) increase in Smad2/3 phosphorylation at 15 min. That said, no differences between the combination of treatments and either TGF␤1 or ethanol alone were detected.
Long-term effects
Twenty-four hour treatments with TGF␤1, ethanol, or TGF␤1 plus ethanol did not induce significant changes in total Smad2/3 content ( Fig. 2; supplemental Table 2 B, available at www. jneurosci.org as supplemental material). The implication from these and the above data on acute changes is that total Smad2/3 recovered to baseline expression. Nevertheless, there was a significant (F (15,135) ϭ 3.39, p Ͻ 0.001) and persisting change in Smad2/3 phosphorylation. That is, Smad2/3 phosphorylation that increased within 15 min was also detected after 24 h of treatment.
Post hoc analyses showed that there were significant ( p Ͻ 0.05) increases in Smad2/3 phosphorylation following treatment with TGF␤1 or ethanol. Furthermore, the effects of ethanol were concentration-dependent; exposures to 200 and 400 mg/dl in- Addition of SB431542 caused a significant ( p Ͻ 0.01) decrease in Smad2/3 phosphorylation in control ( p Ͻ 0.01) and TGF␤1-treated slices. The implication is that SB431542 inhibited the long-term activation induced by endogenous and exogenous TGF␤1. Furthermore, SB431542 blocked Smad2/3 phosphorylation induced by ethanol (200 and 400 mg/dl; p Ͻ 0.01), but it was unable to affect the phosphorylation induced by high concentrations (800 mg/dl) of ethanol.
ERK1/2 phosphorylation
Short-term effects Total ERK1 protein content significantly (F (5,251) ϭ 2.34, p Ͻ 0.05) changed over time, though no effect of treatment was detected ( Fig. 3; supplemental Table 2 A, supplemental Figs. 1 B, 2C ,D, available at www.jneurosci.org as supplemental material). Further, there was no effect of treatment or time on ERK1 phosphorylation.
Neither total ERK2 protein nor phosphorylated ERK2 content was affected by any treatment. Despite this, an ANOVA of the data for the effects of the SB431542 with or without ethanol showed that there was a significant treatment-induced change re the controls. The Smad2/3 inhibitor significantly (F (3,118) ϭ 4.53, p Ͻ 0.01) increased ERK2 phosphorylation after 5 and 90 min of treatment, and this effect was blocked with the addition of ethanol.
Long-term effects
There were significant changes neither on total ERK1 protein ( Fig. 4 ; supplemental Table 2 B, available at www.jneurosci.org as supplemental material) nor on the phosphorylation of ERK1 following chronic (24 h) treatment with TGF␤1, ethanol, and the Smad2/3 and ERK1/2 blockers.
There were no effects of treatment on the total ERK2. In contrast, treatments resulted in a significant main effect on the longterm phosphorylation of ERK2 (F (15,120) ϭ 1.37, p Ͻ 0.01). The significant difference in ERK2 phosphorylation did not result from treatment with chronic treatment with TGF␤1 alone. On the other hand, ethanol (200 and 800 mg/dl) induced significant Effect of chronic treatments on the Smad2/3 signaling. The three-dimensional graphs describe the effects of 24 h treatment with TGF␤1, ethanol (0, 200, 400, or 800 mg/dl), a Smad2/3 inhibitor, and an ERK inhibitor (individually and in combinations) on phosphorylated Smad2/3 (left) and total Smad2/3 (right) content. n ϭ 8. Significant ( p Ͻ 0.05) differences relative to the controls or ethanol-treated preparations are identified by an * or a #, respectively.
R E T R A C T E D
( p Ͻ 0.05 and p Ͻ 0.01, respectively) ERK2 phosphorylation. Chronic inhibition with PD98059 did not cause a significant change in ERK activation. Chronic treatment of slices with both ethanol and PD98059, however, caused a significant ( p Ͻ 0.01) increase in ERK2 phosphorylation at all three ethanol doses. These results suggest that PD98059 [or U0126 (supplemental Fig.  2C ,D, available at www.jneurosci.org as supplemental material)] is incapable of blocking the ethanol-induced phosphorylation of ERK2. It was noted, however, that PD98059 was also incapable of blocking endogenous ERK stimulation at this time point. This may have resulted because the half-life of PD98059 may have been sufficiently short to render it effectively inactive within the 24 h. To address this issue, slices were treated with the ethanol for 24 h and treatment with PD98059 (or U0126) only occurred for the last 30 min. Following this manipulation, both compounds were capable of suppressing ethanol-induced ERK stimulation (supplemental Fig. 2 E, F , available at www.jneurosci.org as supplemental material).
Interplay of the Smad and ERK pathways
Interestingly, ERK2 phosphorylation increased ( p Ͻ 0.05) following treatment with the Smad pathway inhibitor ( Fig. 3 ; supplemental Fig. 1 B, available at www.jneurosci.org as supplemental material). When ethanol was coadministered with SB431542 or LY364947, the amount of phosphorylation did not differ from that of controls. Therefore, ethanol is acting as either an inhibitor to ERK signaling or as a direct blocker of the Smad inhibitor. Conversely, although the administration of PD98059 alone did not affect Smad2/3 phosphorylation, when the PD98059 or U0126 was coadministered with ethanol, there was a robust (fourfold; p Ͻ 0.01) increase in Smad2/3 phosphorylation ( Fig. 1 ; supplemental Fig. 2C ,D, available at www.jneurosci.org as supplemental material). Based on these data, it is evident that (1) ethanol directly stimulated Smad2/3; (2) in the absence of ERK1/2 activation, ethanol stimulates Smad2/3 to an even greater degree; (3) ERK1 was phosphorylated in reaction to Smad inhibition; and (4) ethanol blocked the Smad-inhibited ERK1 activation. 
R E T R A C T E D
Phosphorylation in proliferative and nonproliferating compartments Smad2/3 Localization of activated Smad2/3 in the developing cerebral wall was assessed by immunohistochemistry. Both Smad2/3 protein and phosphorylated Smad2/3 were expressed broadly through the cerebral wall (Fig. 5) . That said, the expression pattern was not consistent; immunolabeling for phosphorylated Smad2/3 was more intense in the IZ/CP/MZ than it was in the S/VZ. Indeed, few cycling (Ki-67ϩ) cells exhibited phosphorylated Smad2/3. Smad2/3 expression remained consistent regardless of the treatment, the compartment, or the duration of the treatment. Despite no visible change in the total Smad2/3 content, the treatment with TGF␤1 and/or ethanol for 15 min (a time by which significant changes were seen in expression assays) caused an apparent increase in the intensity of phosphorylated Smad2/3 immunolabeling in both compartments including an increase in Ki-67 double labeling. SB431542 inhibited the phosphorylated Smad2/3 expression in TGF␤1-and ethanol-treated sections.
Immunohistochemical preparations did not permit quantification of the expression and activation profiles in discrete segments of the cerebral wall. Hence, immunoblotting of microdissected samples of the proliferative (S/VZ) and postproliferative (IZ/CP/MZ) compartments was examined (supplemental Fig. 3A , available at www.jneurosci.org as supplemental material). The amount of total Smad2/3 was not significantly different in the two compartments (Fig. 6) or following the various treatments. Moreover, no significant compartment by treatment interaction was detected.
As demonstrated in the immunoblots, the amount of phosphorylated Smad2/3 was fourfold higher in the postproliferative compartment than in the proliferative compartment ( Fig. 6 ; supplemental Fig. 3A , available at www.jneurosci.org as supplemental material); this difference was statistically significant (F (1,70) ϭ 4.26; p Ͻ 0.05). There was, however, no effect of treatment in the postproliferative compartment. The pattern in the proliferative compartment was quite different. A significant (F (7,85) ϭ 3.027; p Ͻ 0.01) effect of treatment on Smad2/3 phosphorylation was seen in the proliferative compartment. The increases in Smad2/3 occurred following treatment with TGF␤1 ( p Ͻ 0.05), ethanol ( p Ͻ 0.05), or TGF␤1 and ethanol ( p Ͻ 0.05). The Smad2/3 inhibitor blocked stimulation via both TGF␤1 ( p Ͻ 0.05) and ethanol ( p Ͻ 0.05).
ERK1/2
Sections were immunostained for phosphorylated ERK1/2 and Ki-67 expression (Fig. 7) . Profiles that were phosphorylated ERK-positive had long processes that extended from the VZ through the cortical plate. According to an omnibus ANOVA, total ERK1 protein was not altered by various treatments (Fig. 8) . There was no effect of treatment or by compartment, nor was there a treatment ϫ compartment interaction. A separate ANOVA for the effects of the Smad2/3 inhibitor with or without ethanol in the proliferative compartment was performed. This showed a significant (F (3,12) ϭ 8.216; p Ͻ 0.05) difference. The SB431542 treatment in combination with ethanol induced a fivefold increase relative to treatment with the SB431542 alone and sixfold versus the ethanol treatment alone; both differences were statistically significant ( p Ͻ 0.01). Further, there was a significant increase in the phosphorylation of ERK1 via treatment (F (7,85) ϭ 2.66; p Ͻ 0.05), compartment (F (1,85) ϭ 3.94; p Ͻ 0.05) and a treatment ϫ compartment interaction (F (7,85) ϭ 2.28; p Ͻ 0.05). In the case of ERK1, the effects of treatment were due to a TGF␤1-( p Ͻ 0.01) or ethanol-induced ( p Ͻ 0.01) increase in phosphorylated ERK1 expression in the postproliferative compartment only. Again, as with ERK1, combined treatment with TGF␤1 and ethanol attenuated the effect caused by treatment with TGF␤1 or ethanol alone and reduced expression to amounts detected in controls.
The quantitative immunoblotting analysis showed that ERK2 was affected in inverse manner from the Smad pathway. There was a significant (F (1,85) ϭ 5.74; p Ͻ 0.05) effect of the compartment on the amount of total ERK2 protein ( Fig. 8; supplemental Fig. 3B , available at www.jneurosci.org as supplemental material), with more ERK2 being expressed in the proliferative com- 
Additionally, there was a significant effect of treatment on ERK2 total protein (F (7,85) ϭ 3.26; p Ͻ 0.01) and phosphorylation (F (7,85) ϭ 4.50; p Ͻ 0.01). Post hoc analyses revealed that ethanol significantly ( p Ͻ 0.01) increased the phosphorylation of ERK2 in both zones. When TGF␤1 and ethanol were given in combination, the amount of phosphorylation was attenuated relative to the controls. Furthermore, both SB431542 and PD98059 inhibited the ethanol-induced ERK2 phosphorylation.
Discussion
TGF␤1 signaling
The developing telencephalon has an endogenous TGF␤ signaling system that can be activated. The endogenous nature is evident in the ability of SB431542 to inhibit Smad2/3 in otherwise untreated slices. The active nature is evident in the ability of exogenous TGF␤1 to stimulate Smad2/3 and ERK1/2, and that this activation can be inhibited with specific blockers. Such findings corroborate anatomical studies showing that TGF␤ ligands and receptors are expressed in the developing forebrain (Miller, 2003) . Smad2/3 and ERK1/2 play particular roles in early cortical development. Although Smad2/3 is distributed throughout the cerebral wall, TGF␤1 selectively induces Smad2/3 activity in the proliferative compartment. In the postproliferative compartment, TGF␤1 acts constitutively and ERK1/2 activation is inductive. The morphology of phosphorylated ERK1/2-positive profiles in cerebral wall is like that for TGF␤ ligand-and receptor-positive processes (Miller, 2003) . Presumably these profiles are radial glia which serve as neural stem cells (Malatesta et al., 2000; Suter and Bhide, 2006) and guides for neuronal migration (Rakic, 1972; Hu, 2006) . Therefore, we posit (1) that TGF␤-regulated Smad2/3 activation is key for cell proliferation and (2) that ERK1/2 is particularly important in TGF␤-affected neuronal migration.
Ethanol-induced stimulation of the TGF␤1 pathway
Exposure to ethanol provides insights into the response characteristics of the two TGF␤-initiated pathways. An early response to ethanol is stimulation of Smad2/3; ethanol triggers a TGF␤-like mechanism. The ethanol-induced activation follows the same timeline as TGF␤1-induced activation, occurs in the presence of a serum-free, growth factor-free medium, i.e., in the absence of detectable amounts of TGF␤ (Lindke et al., 2005) , and proceeds in the absence of a change in Smad2/3 protein content. Ethanolinduced phosphorylation of Smad2/3 is blocked by SB431542; implying that ethanol action requires TGF␤ receptor mediation. The present findings conflict with those of Chaturvedi and Sarkar (2005) in folliculostellate cells, which show that ethanol does not affect Smad phosphorylation. Presumably the difference arises from Chaturvedi and Sarkar's (2005) use of serum in their medium and the possible masking of the induction by serum-borne factors.
Ethanol affects ERK1 activation in isolated proliferative and postproliferative compartments and ERK2 phosphorylation in the postproliferative compartment. The short time and the concurrence of the activation of the two pathways imply that the effects are direct and parallel. The ethanol-induced stimulation of the ERK1/2 pathway is blocked by specific inhibitors. The effects of ethanol on ERK1/2 complement changes detected among dissociated cultures of proliferating cortical astrocytes (Luo and Miller, 1999b) , B104 neuroblastoma cells (Luo and Miller, 1999) , and fetal cortical neurons (Kalluri and Ticku, 2003) . Conceivably, upregulation of ERK1/2 results after Smad2/3-mediated cessation of cell proliferation. This "handoff" likely results in the initiation of neuronal migration. At the chronic time point, ethanol induces ERK1/2 activation when there are no changes induced by TGF␤. The ERK signaling pathway is promiscuous, inducing many other receptor systems present in the developing cortex, including brain-derived neurotrophic factor (Barnabé-Heider and Miller, 2003) and neurotrophin-3 (Ohtsuka et al., 2009) . Therefore, ethanol induced changes in ERK2 phosphorylation in the absence of induction by TGF␤1. Thus, the effects of ethanol on the ERK1/2 pathway are transduced through a nonTGF␤r-mediated mechanism.
There are multiple possible mechanisms by which ethanol affects TGF␤-regulated signaling. (1) Ethanol enhances the binding of TGF␤1 to its receptor. This is unlikely, at least in the present situation, because the serum-free medium is virtually devoid of TGF␤1 ligand even after 24 h of conditioning (Lindke et al., 2005) . That said, slices raised in the serum-free medium do exhibit detectable amounts of constitutive Smad2/3 phosphorylation, implying that there is sufficient TGF␤1 ligand binding or that there is another mechanism through which Smad2/3 can be phosphorylated. (2) Ethanol competitively binds to a TGF␤ receptor. This idea is supported by evidence that combined TGF␤1 and ethanol treatment does not produce an additive response. 
R E T R A C T E D
Possibly the stimulation produced by either of these compounds saturates the receptor population blocking any further phosphorylation. PD98059 treatment results in the stimulation of Smad2/3 phosphorylation beyond that seen with TGF␤1 and ethanol. This suggests that these cells are capable of higher levels of stimulation. It is uncertain how the ERK blockade induces this stimulation of Smad2/3. (3) Finally, ethanol directly affects intracellular regulators, e.g., Smad2/3 and ERK1/2. Neither TGF␤1 nor ethanol increases the amount of phosphorylated Smad2/3 beyond that induced by either compound alone. Conversely, the coadministration of these two substances abolishes the stimulatory effect either individual compound has on the ERK1/2 pathway, thus, returning the amount ERK1/2 phosphorylation back to that detected in controls. The present data concur with studies of dividing neuroblastoma cells (Luo and Miller, 1999a) wherein combined treatment with TGF␤1 and ethanol produces ERK1/2 activation like that in controls.
Interplay between the Smad2/3 and ERK1/2 pathways Cross talk between the Smad2/3 and ERK1/2 pathways has been described in non-nervous tissue. This cross talk may be due to the presence of four ERK phosphorylation sites on the linker regions of Smad2 and Smad3 (Shi and Massagué, 2003; Matsura et al., 2005) . Phosphorylation of these ERK sites leads to TGF␤/Smad potentiation (Liu et al., 1998) via enhancement of heterodimerization of Smad 4, transcriptional activity and translocation of the Smads (de Caestecker et al., 1998) . TGF␤1-initiated ERK signaling occurs through induction of the Ras/Raf pathway (Kretzschmar et al., 1999) (Fig. 9) . The directionality of the ERK effect on Smads seems to be system dependent. In tumor cell lines, Ras activation inhibits TGF␤1 signaling through Smads (Kretzschmar et al., 1999) , whereas in epithelial cells, cooperation exists between Ras/ ERK1/2 signaling and TGF␤ expression (Oft et al., 1996; Lehmann et al., 2000) .
In the cerebral wall, inhibition of ERK1/2 alone does not lead to a change in Smad2/3 activation. Ethanol administered in conjunction with an ERK pathway blockade produces a fourfold increase in Smad2/3 signaling. This phosphorylation is twofold greater than that of ethanol alone. Pretreatment with PD98059 diminishes the phosphorylation of immunoprecipitated Smad2/3 protein, but does not effect TGF␤-induced Smad2/3 phosphorylation (Hayashida et al., 2003) . It is not surprising that PD98059 does not induce a detectable change in Smad2/3 phosphorylation. After all, administration of PD98059 in the present study was concurrent with TGF␤1 or ethanol. Intriguingly, ethanol has the ability to override the PD98059 blockade and to function cooperatively to cause hyperstimulation of Smad2/3. Thus, the site of ethanol action may lie within the communication between the Smad2/3 and ERK1/2 pathways. Ethanol is more effective at stimulating the Smads when the ERK pathway is inhibited, yet blocks the Smad-inhibition induced ERK pathway.
Stimulation of ERK1/2 can induce TGF␤ expression. Direct Smad-induced ERK activation can be differentiated from indirect activation by differences in the kinetics. TGF␤ stimulation through ERK1/2 is rapid, whereas Smad-mediated ERK1/2 activation takes longer. Based on this time course, ethanol-and TGF␤-induced phosphorylation of ERK1/2 is direct. The phosphorylation that occurs in each pathway following the blockade of the opposing pathway, however, is mediated via an indirect mechanism.
Blocking the Smad2/3 pathway with SB431542 leads to a pronounced increase in the phosphorylation of ERK1/2. The amount exceeds that caused by either TGF␤1 or ethanol alone. This SB431542-induced activity is blocked by ethanol. Therefore, the 
Clinical ramifications
TGF␤1 is an important mediator of ethanol-induced teratogenicity. TGF␤1 and ethanol alter cell proliferation (Miller and Nowakowski, 1991; Miller and Luo, 2002a,b; Siegenthaler and Miller, 2005a,b) and migration (Miller, 1993; Mooney et al., 2004; Siegenthaler and Miller, 2004; Kumada et al., 2006) . The present study elucidates a mechanism through which ethanol acts, i.e., via direct stimulation of TGF␤1-responsive Smad2/3 and ERK1/2 pathways. The change in Smad2/3 activation may prematurely push cells out of the cell cycle and promote their migration. Ethanol mimics TGF␤1-induced ERK1/2 stimulation, however, when administered in conjunction with TGF␤1, ERK1/2 phosphorylation is less than that caused by either compound alone. That said, the complexity of an in vivo microenvironment must be considered. In an in vivo situation, ethanol is present with ambient growth factors including TGF␤1. Further, if migration is an ERK1/2-mediated event, as the present study suggests, then ethanol-induced suppression of endogenous TGF␤1-regulated ERK1/2 signaling underlies the ethanol-induced abnormalities in neuronal migration. Thus, it is through the dysregulation of these two developmental events that the ethanolinduced defects in cell production and aberrant neuronal migration contribute to FASD-associated defects.
Ethanol induces abnormalities in neural development that are common to many pathological states. For example, exposure to toxic substances, e.g., valproic acid (Hanson and Smith, 1975; Adams et al., 1990; Li et al., 2005) , toluene (Gospe and Zhou, 2000) , and cocaine (Lidow and Song, 2001; Crandall et al., 2004) , replicate changes in cell proliferation and migration occurring in experimental FASD. Alterations caused by hypothyroidism (Lucio et al., 1997; Lavado-Autric et al., 2003; Goodman and Gilbert, 2007) and genetic disorders such as Down's syndrome-like trisomy (Cheng et al., 2004; Chakrabarti et al., 2007 ) also affect brain development in ways that parallel ethanol teratogenicity. Thus, the changes described in the present study may underlie the neurodevelopmental disabilities seen in children who have FASD or parallel impairments. 
